This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

4SC-203

4SC AG

Drug Names(s): 4SC-203

Description: 4SC-203 is a novel, small molecule, multi-targetkinase inhibitor which has a unique selectivityprofile against FLT3, FLT3 mutants and VEGF-receptors. FLT3 is involved in the growth and maturation of normal blood cells, while VEGF receptor tyrosine kinases are involved in angiogenesis.

4SC-203 News

Scrip Celltrion Hit By Truxima Price Cut, Temporary Utilization Rate Drop

Scrip Aveo Eyes Role For Tivozanib In US Kidney Cancer Market, Against The Odds

Scrip Pipeline Watch: Phase III Starts With Murepavadin, Infigratinib And Mavacamten

Scrip Finance Watch: Vaccinex, Aridis Launch August's First US IPOs As The Summer Simmer Slows

Additional information available to subscribers only:

Targets
Routes
Catalysts
Designations
Events

Request a Free Demo Subscriber Login Search for another drug